72702-57-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-CHLOROPHENYL)-2-BROMOETHANOL is used as an active ingredient for its antimicrobial and antifungal properties, contributing to the development of medications targeting various infections.
Used in Disinfectant and Preservative Production:
1-(2-CHLOROPHENYL)-2-BROMOETHANOL is used as a key component in the manufacturing of disinfectants and preservatives due to its ability to inhibit the growth of microorganisms, ensuring cleanliness and preventing spoilage.
Used in Organic Synthesis:
1-(2-CHLOROPHENYL)-2-BROMOETHANOL is used as a versatile building block in organic chemistry for the synthesis of other chemical compounds, such as esters and ethers, broadening its applications across different industries.
It is crucial to handle 1-(2-CHLOROPHENYL)-2-BROMOETHANOL with care, as it is classified as a hazardous substance that can cause irritation to the skin, eyes, and respiratory system.

Upstream product

• 5000-66-8 2-chlorophenacyl bromide 
• 2142-68-9 1-(2-chlorophenyl)ethanone 
• 2039-87-4 2-chlorostyrene 

Downstream Products

• 62717-50-4 o-chlorostyrene oxide 
• 333309-74-3 (E)-1-(2'-chlorophenyl)-2-bromoethylene 
• 187463-09-8 (Z)-1-(2-bromovinyl)-2-chlorobenzene 
• 1212322-23-0 2-bromo-1-(2-chlorophenyl)ethan-1-ol 
• 41570-61-0 tulobuterol 
• 1608496-96-3 C₂₄H₂₇ClN₂O₄ 
• 1608496-87-2 C₁₉H₁₉ClN₂O₂ 
• 1613220-26-0 C₂₄H₂₈BrClN₂O₄ 
• 142363-73-3 2-(2-chlorophenyl)-4-n-propylmorpholine 
• 142363-69-7 6-(2-chlorophenyl)-4-n-propylmorpholin-3-one 
• 142363-65-3 1-(2-chlorophenyl)-2-(n-propylamino)ethanol 
• 56203-04-4 1-(2-chlorophenyl)-2-{[2-(phenylacetamido)ethyl]amino}ethanol 

Relevant academic research and scientific papers

Tulobuterol crystal form and preparation method thereof

The invention provides a tulobuterol crystal form and a preparation method thereof. The preparation method comprises the following steps of: dissolving tulobuterol in ethyl acetate and other good solvents, dropwisely adding n-heptane and other poor solvents into the system, filtering, taking the filter cake, and drying the filter cake to obtain the tulobuterol crystal form crystal. The crystal form is high in purity and good in stability, has superiority in process production, and is suitable for long-term storage in the preparation process.

Lipase mediated enzymatic kinetic resolution of phenylethyl halohydrins acetates: A case of study and rationalization

Racemic phenylethyl halohydrins acetates containing several groups attached to the aromatic ring were resolved via hydrolysis reaction in the presence of lipase B from Candida antarctica (Novozym 435). In all cases, the kinetic resolution was highly selective (E > 200) leading to the corresponding (S)-β-halohydrin with ee > 99 %. However, the time required for an ideal 50 % conversion ranged from 15 min for 2,4-dichlorophenyl chlorohydrin acetate to 216 h for 2-chlorophenyl bromohydrin acetate. Six chlorohydrins and five bromohydrins were evaluated, the latter being less reactive. For the β-brominated substrates, steric hindrance on the aromatic ring played a crucial role, which was not observed for the β-chlorinated derivatives. To shed light on the different reaction rates, docking studies were carried out with all the substrates using MD simulations. The computational data obtained for the β-brominated substrates, based on the parameters analysed such as NAC (near attack conformation), distance between Ser-O and carbonyl-C and oxyanion site stabilization were in agreement with the experimental results. On the other hand, the data obtained for β-chlorinated substrates suggested that physical aspects such as high hydrophobicity or induced change in the conformation of the enzymatic active site are more relevant aspects when compared to steric hindrance effects.

INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS

This disclosure relates to compounds (I), pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to glioma-associated oncogene (Gli) expression. More particularly, this disclosure relates to bicyclic compounds and pharmaceutical compositions thereof, methods of inhibiting Gli expression with these compounds, and methods of treating diseases related to Gli expression.

Preparation method of tulobuterol

The invention provides a preparation method of tulobuterol. The technical problems of potential safety hazard, complicated post-treatment and the like in the existing method are solved. According to the method, a compound 1-(2-chlorphenyl)-2-tert-butylaminoethanol is synthesized from industrially available 2-chlorostyrene through a two-step reaction. The method is short in reaction step, mild in reaction condition, simple and convenient to operate, high in yield and good in application and development prospect, and can be used for preparing tulobuterol.

Method for synthesizing tulobuterol

The invention discloses a method for synthesizing tulobuterol. According to the method, 1-(2-chlorophenyl)-2-bromoethanone (compound 3) and 1-(2-chlorophenyl)-2,2-dibromoethanone (compound 10) can besimultaneously utilized to synthesize the tulobuterol. In an original route, the compound 10 is a by-product of synthesis of the compound 3, and about 10-15% of the compound 10 is not fully utilized.The method provided by the invention can improve the synthesis yield of the tulobuterol, is simple to operate, is environmentally friendly, is low in cost and is suitable for industrial production.

NOVEL DITHIOLANE COMPOUND OR A SALT OR AN N-OXIDE AND USE THEREOF

An object of the present invention is to provide a dithiolane compound or a salt or an N-oxide thereof that controls diseases. The present invention provides a dithiolane compound represented by Formula (1) or a salt or an N-oxide thereof, wherein R1 represents hydrogen, halogen, C1-6 alkyl or a substituent as defined herein; R2 represents hydrogen, halogen, C1-6 alkyl or a substituent as defined herein; R3 represents hydrogen, halogen, C1-6 alkyl or a substituent as defined herein; Y1 represents optionally substituted aryl, optionally substituted pyridyl or a substituent as defined herein; Y2 represents optionally substituted aryl, optionally substituted pyridyl or a substituent as defined herein; Q represents cyano or a substituent as defined herein.

Lactam and oxazolidinone derived potent 5-hydroxytryptamine 6 receptor antagonists

Lactam and oxazolidinone derived potent 5-hydroxytryptamine 6 (5-HT 6) receptor antagonists have been disclosed. One potent member from the lactam series, racemic compound 14 (Ki of 2.6 nM in binding assay, IC50 of 15 nM in functional cAMP antagonism assay) was separated into corresponding enantiomers that displayed the effect of chirality on binding potency (Ki of 1.6 nM and 3000 nM, respectively). The potent enantiomer displayed an IC50 of 8 nM in cAMP antagonism assay, selectivity against a number of family members as well as brain permeability in rats after 6 h post oral administration.

5- substituted tetralones as inhibitors of ras farnesyl trransferase

The present invention provides novel 5-substituted tetralones of Formulas (I), (II), (III) and (IV) and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme.

Oxygen Isosteric Derivatives of 3-(3-Hydroxyphenyl)-N-n-propylpiperidine

Some substituted 3-phenylmorpholines (10a-e,j,k) and 3-thienylmorpholines (10f,g), isosteres of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP), were prepared and submitted to binding assays on D-2 dopaminergic and 5-HT1 and 5-HT2 serotonergic receptors, in comparison with 3-PPP and its analogue 3a,b.The results show the loss of D-2 affinity for all morpholines, while a certain activity was still observable for piperidine derivatives.Regarding the serotonergic affinity, only chloro and methoxy derivatives (10a-d) were moderately active on the 5-HT1A receptor, either when the substituent was in the C-2 or C-3 position, whereas no tested compounds showed affinity toward the 5-HT2 receptor.